Sphingomyelinase Licensing of Mesenchymal Stromal Cells Alters Lipid and Protein Metabolites for Immunomodulation
S’Dravious A. DeVeaux, Daniel C. Shah, Kejie Rui, Nathan F. Chiappa, Hongmanlin Zhang, Nidhi Lal, Rhyland O’Neill, Young Charles Jang, Luke J. Mortensen, Krishnendu Roy, Edward A. Botchwey
This study shows that sphingomyelinase treatment alters lipid and protein metabolites in MSCs, enhancing their immunomodulatory properties similar to cytokine-based priming.
bioRxiv · Jul 17, 2025 · PreprintBioengineering